Shanghai ZJ Bio-Tech Management

Management criteria checks 2/4

Shanghai ZJ Bio-Tech's CEO is Junbin Shao, appointed in May 2023, has a tenure of 1.5 years. directly owns 0.35% of the company’s shares, worth CN¥12.35M. The average tenure of the management team and the board of directors is 9.1 years and 3.7 years respectively.

Key information

Junbin Shao

Chief executive officer

CN¥1.3m

Total compensation

CEO salary percentage	n/a
CEO tenure	1.5yrs
CEO ownership	0.3%
Management average tenure	9.1yrs
Board average tenure	3.7yrs

Recent management updates

Recent updates

CEO

Junbin Shao (53 yo)

1.5yrs

Tenure

CN¥1,289,000

Compensation

Mr. Junbin Shao serves as Chairman and Director at Shanghai ZJ Bio-Tech Co., Ltd. since August 2011 and serves as its General Manager since May 2023 and serves as its Dean of Research Institute & Director...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Junbin Shao	Chairman	1.5yrs	CN¥1.29m	0.35% CN¥ 12.4m
Weiqin Ni	Deputy GM	13.3yrs	CN¥1.05m	0.021% CN¥ 730.4k
Kai Wang	Deputy General Manager	4.8yrs	CN¥1.98m	no data
Yiyun Wang	Deputy General Manager	1.8yrs	CN¥832.80k	no data
Feng Shu	Synthesis Department Manager	9.1yrs	CN¥333.10k	no data
Peixiao Li	Production Manager	9.1yrs	CN¥408.50k	no data
Qinwei Zhu	Director of Product Development Center & Manager of Project Management Department	9.1yrs	CN¥509.60k	no data
Jie Zhang	Core Technical Staff	9.1yrs	no data	no data
Yan Liu	Research Director	9.1yrs	no data	no data

9.1yrs

Average Tenure

43yo

Average Age

Experienced Management: 688317's management team is seasoned and experienced (9.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Junbin Shao	Chairman	13.3yrs	CN¥1.29m	0.35% CN¥ 12.4m
Weiqin Ni	Deputy GM	13.3yrs	CN¥1.05m	0.021% CN¥ 730.4k
Xueyao Li	Independent Director	4.5yrs	CN¥95.20k	no data
Yongsheng Yu	Independent Director	4.5yrs	CN¥95.20k	no data
Jingming Ma	Director	2.8yrs	CN¥163.30k	no data
Haiyang Lin	Chairman of the Supervisory Board	1.5yrs	no data	no data
Xuerui Liu	Employee Representative Supervisor	1.5yrs	no data	no data
Ai Wang	Employee Representative Supervisor	1.8yrs	no data	no data

3.7yrs

Average Tenure

45yo

Average Age

Experienced Board: 688317's board of directors are considered experienced (3.7 years average tenure).

Shanghai ZJ Bio-Tech Management

Management criteria checks 2/4

Key information

Recent management updates

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.21 loss per share (vs CN¥0.015 profit in 3Q 2023)

Shanghai ZJ Bio-Tech Co., Ltd to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.005 loss per share (vs CN¥0.15 profit in 2Q 2023)

Shanghai ZJ Bio-Tech Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings released: CN¥0.71 loss per share (vs CN¥3.93 profit in FY 2022)

Shanghai ZJ Bio-Tech Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Full year 2023 earnings released: CN¥0.67 loss per share (vs CN¥3.93 profit in FY 2022)

Shanghai ZJ Bio-Tech Co., Ltd. (SHSE:688317) announces an Equity Buyback for CNY 70 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Now 27% undervalued after recent price drop

Third quarter 2023 earnings released: EPS: CN¥0.015 (vs CN¥0.81 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥1.04 in 2Q 2022)

Shanghai ZJ Bio-Tech Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Full year 2022 earnings released: EPS: CN¥3.93 (vs CN¥3.98 in FY 2021)

Full year 2022 earnings released: EPS: CN¥3.82 (vs CN¥3.98 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.81 (vs CN¥1.11 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.04 (vs CN¥0.36 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥3.98 (vs CN¥6.38 in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Bispecific antibody drug against COVID-19 jointly developed by Shanghai ZJ Bio-Tech and Sanyou Biopharmaceuticals appearing at China International Import Expo

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥2.27 in 2Q 2020)

Investor sentiment improved over the past week

CJ Cheiljedang Corporation (KOSE:A097950) signed a stock purchase contract to acquire 15.99% stake in ChunLab, Inc. (KOSDAQ:A311690) from Jong-sik Cheon and Shanghai ZJ Bio-Tech Co., Ltd. (SHSE:688317) for KRW 25 billion.

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥6.38 (vs CN¥0.35 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Shanghai ZJ Bio-Tech Co., Ltd. to Report Fiscal Year 2020 Results on Apr 22, 2021

Shanghai ZJ Bio-Tech Co., Ltd. has completed an IPO in the amount of CNY 2.103781 billion.

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age